ArticleJournal of research in medical sciences : the official journal of Isfahan University of Medical Sciences2010
Intravenous bisphosphonates for postmenopausal osteoporosis.
Article in Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.
- Dose-Effectiveness Relationships Determining the Efficacy of Ibandronate for Management of Osteoporosis: A Meta-Analysis.Medicine · 2015Pooled it
- An acute phase reaction from zoledronate mimicking symptoms seen in opioid withdrawal: a case report.Addiction science & clinical practice · 2024Article
- Antioxidant and Bone; Protect Your Future: A Brief Review.Iranian journal of public health · 2021Review
- May zoledronic acid have negative effects on cognition and muscle performance?Irish journal of medical science · 2020Article
- Combination of alendronate and genistein synergistically suppresses osteoclastic differentiation of RAW267.4 cellsExperimental and therapeutic medicine · 2017Article
- Cost-Effectiveness of Zoledronic Acid to Prevent and Treat Postmenopausal Osteoporosis in Comparison with Routine Medical Treatment.Electronic physician · 2016Article
- Current Clinical Practice Scenario of Osteoporosis Management in India.Journal of clinical and diagnostic research : JCDR · 2015Article
- The molecular etiology and treatment of glucocorticoid-induced osteoporosis.Tzu chi medical journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Numerous clinical studies have shown bisphoshonates (BPs) to be useful and cost-effective options for the fractures prevention and postmenopausal bone loss. The use of oral bisphoshonates is an established option for managment of osteoporosis in postmenopausal women, but many of them complaint from gastrointestinal side effect or frequently dosed oral regimens. To improve upon the suboptimal therapeutic compliance in postmenopausal women, newer, longer-acting intravenous formulations of BPs has been approved for intermittent administration in postmenopausal women. These preparations would become an option for patients who can not tolerate oral BPs or it was ineffective in increasing their bone density.This article proposed to review effectiveness and tolerability of intravenous BPs in postmenopausal women with osteoporosis.
Indexed as
Identifiers
21526078PMC3082804W2150489401What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.